This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey
The transaction is expected to close in Q2 FY 2026
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The company received seven observations in the Form-483
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
The company received one observation in the Form-483
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Sun Pharma gets 8 observations from USFDA for Halol facility
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Subscribe To Our Newsletter & Stay Updated
